130 related articles for article (PubMed ID: 19043301)
1. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection.
Okuda T; Okuda A; Watanabe N; Takao M; Takayanagi K
Yakugaku Zasshi; 2008 Dec; 128(12):1811-8. PubMed ID: 19043301
[TBL] [Abstract][Full Text] [Related]
2. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.
Hamada Y; Seto Y; Yago K; Kuroyama M
J Infect Chemother; 2012 Aug; 18(4):501-7. PubMed ID: 22231601
[TBL] [Abstract][Full Text] [Related]
3. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
5. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
7. [Case of Scedosporium apiospermum cutaneous soft tissue infection treated with voriconazole].
Konishi M; Yonekawa S; Nakagawa C; Uno K; Kasahara K; Yoshimoto E; Maeda K; Mikasa K
Kansenshogaku Zasshi; 2008 Mar; 82(2):82-5. PubMed ID: 18411765
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
10. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation.
Trifilio SM; Yarnold PR; Scheetz MH; Pi J; Pennick G; Mehta J
Antimicrob Agents Chemother; 2009 May; 53(5):1793-6. PubMed ID: 19223632
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis].
Hagiwara E; Shiihara J; Matsushima A; Enomoto T; Tagawa A; Sekine A; Tsuchiya N; Baba T; Shinohara T; Endo T; Sogo Y; Nishihira R; Komatsu S; Kato T; Ogura T; Takahashi H
Nihon Kokyuki Gakkai Zasshi; 2009 Feb; 47(2):93-7. PubMed ID: 19260530
[TBL] [Abstract][Full Text] [Related]
12. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
Shima H; Miharu M; Osumi T; Takahashi T; Shimada H
Pediatr Blood Cancer; 2010 Jul; 54(7):1050-2. PubMed ID: 20146339
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and treatment of pulmonary aspergillosis. Role of voriconazole (discussion)].
Kohno S; Ogawa K; Kurashima A; Niki Y; Maesaki S
Jpn J Antibiot; 2007 Dec; 60(6):321-34. PubMed ID: 18447204
[No Abstract] [Full Text] [Related]
14. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
15. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.
Koh H; Hino M; Ohta K; Iino M; Urase F; Yamaguchi M; Yamanouchi J; Usui N; Yoshida M; Tanimoto M; Ohyashiki K; Urabe A; Tamura K; Kanamaru A; Masaoka T
J Infect Chemother; 2013 Dec; 19(6):1126-34. PubMed ID: 23813092
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
17. Intravenous voriconazole after toxic oral administration.
Alffenaar JW; van Assen S; de Monchy JG; Uges DR; Kosterink JG; van der Werf TS
Antimicrob Agents Chemother; 2010 Jun; 54(6):2741-2. PubMed ID: 20385853
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
19. [A case of lung scedosporiosis successfully treated with monitoring of plasma voriconazole concentration level].
Ogata R; Hagiwara E; Shiihara J; Ogura T; Takahashi H; Kamei K
Nihon Kokyuki Gakkai Zasshi; 2011 May; 49(5):388-92. PubMed ID: 21688649
[TBL] [Abstract][Full Text] [Related]
20. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
Imataki O; Ohnishi H; Kitanaka A; Kubota Y; Ishida T; Tanaka T
Int J Hematol; 2008 Jul; 88(1):3-6. PubMed ID: 18574651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
